Fidelity SPDR Advertisement
Home > Boards > US OTC > Biotechs > Nuvilex, Inc. (NVLX)

NVLX

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
NYC Trader Member Profile
Member Level 
Followed By 1,142
Posts 122,226
Boards Moderated 8
Alias Born 01/25/09
160x600 placeholder
Nuvilex’s Partner Austrianova Successfully Completes First Live-Cell Encapsulation in New Facility "InvestorsHub NewsWire" - 12/18/2014 9:30:00 AM
Nuvilex Provides Shareholder Update on Cancer and Diabetes Programs "InvestorsHub NewsWire" - 12/16/2014 9:30:00 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 12/15/2014 4:51:43 PM
Nuvilex Provides Update on Significance of Austrianova’s cGMP Live-Cell Encapsulation Facility "InvestorsHub NewsWire" - 12/10/2014 9:30:00 AM
Nuvilex Announces Name Change of Subsidiary to Viridis Biotech "InvestorsHub NewsWire" - 12/8/2014 9:30:00 AM
Nuvilex Announces the Opening of Austrianova’s cGMP Live Cell Encapsulation Facility in Thailand "InvestorsHub NewsWire" - 12/4/2014 9:30:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 12/2/2014 5:29:36 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 12/1/2014 9:30:48 AM
Nuvilex Obtains Exclusive Worldwide License to Develop Disease Treatments Combining Cell-in-a-Box and Cannabinoid-Based Medic... "InvestorsHub NewsWire" - 12/1/2014 9:30:00 AM
Nuvilex Announces the Formation of a Diabetes Consortium for the Development of Its Treatment for Insulin-Dependent Diabetes "InvestorsHub NewsWire" - 11/24/2014 9:20:00 AM
Nuvilex Executives in Southeast Asia To Further Advance Cell-in-a-Box Technology "InvestorsHub NewsWire" - 11/21/2014 9:30:00 AM
Nuvilex Announces Preliminary Data from Preclinical Study on Effects of Pancreatic Cancer Treatment on Ascites Fluid Formation "InvestorsHub NewsWire" - 11/19/2014 9:30:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 11/12/2014 12:27:25 PM
Nuvilex Applies in Australia for the Orphan Drug Designation for Pancreatic Cancer Treatment "InvestorsHub NewsWire" - 11/7/2014 9:37:08 AM
Prospectus Filed Pursuant to Rule 424(b)(2) (424b2) "Edgar (US Regulatory)" - 10/29/2014 8:20:03 AM
Notice of Effectiveness (effect) "Edgar (US Regulatory)" - 10/29/2014 6:01:20 AM
Securities Registration Statement (simplified Form) (s-3/a) "Edgar (US Regulatory)" - 10/24/2014 5:01:34 PM
Nuvilex Contracts with University of Veterinary Medicine in Vienna to Conduct Preclinical Studies to Develop Diabetes Treatment "InvestorsHub NewsWire" - 10/20/2014 9:00:00 AM
Securities Registration Statement (simplified Form) (s-3) "Edgar (US Regulatory)" - 10/17/2014 4:00:54 PM
Amended Annual Report (10-k/a) "Edgar (US Regulatory)" - 10/17/2014 5:59:23 AM
Amended Annual Report (10-k/a) "Edgar (US Regulatory)" - 10/17/2014 5:59:23 AM
Nuvilex Secures Worldwide License for Insulin-Producing Cells for Use in Developing Diabetes Treatment "InvestorsHub NewsWire" - 10/16/2014 9:00:00 AM
Confidential Treatment Order (ct Order) "Edgar (US Regulatory)" - 10/15/2014 2:13:17 PM
Nuvilex Applies to FDA for Orphan Drug Designation for its Cell-in-a-Box® Treatment for Pancreatic Cancer "InvestorsHub NewsWire" - 10/13/2014 9:00:00 AM
Nuvilex Appoints Dr. Matthias Löhr as Chairman of Scientific Advisory Board "InvestorsHub NewsWire" - 10/6/2014 9:00:00 AM
NYC Trader Member Level  Friday, 05/10/13 07:49:08 AM
Re: None
Post # of 28747 
NVLX
Link: http://www.otcmarkets.com/stock/NVLX/company-info
Ticker: $NVLX
OTC Market Tier: OTCQB
CIK code: 0001157075
Company name: Nuvilex, Inc.
Company website: http://www.nuvilex.com
Incorporated In: NV, USA


Visit my board"NY Penny Stock Exchange" for today's pick at http://investorshub.advfn.com/boards/board.aspx?board_id=16752
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist